Pharmaceuticals Hong Kong

Hong Kong Blood Plasma Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Hong Kong Blood Plasma Market Analysis Industry Trends and Forecast to 2034: Segmented by (By Type, By Application, By End User, By Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Buy the full report

Report snapshot

Hong Kong Blood Plasma Market Analysis at a glance
Market size, 2025Researched figures come with the full report
Forecast, 2034Researched figures come with the full report
Growth (CAGR), 2025–2034Researched figures come with the full report
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, application and end-user (see all)
Key playersCSL Behring, Grifols, Octapharma, Kedrion Biopharma, Biotest LLC and 1 more (see all)
Regulator in Hong KongDrug OfficeSource: Drug Office, Department of Health. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

The Hong Kong Blood Plasma Market Analysis Executive Summary

Plasma, also known as blood plasma, appears light-yellowish or straw-coloured. It serves as the liquid base for whole blood. Whole blood minus erythrocytes (RBCs), leukocytes (WBCs), and thrombocytes (platelets) make up the plasma. Every 2 seconds someone in the U.S. needs blood and or platelets. Approximately 29,000 units of red blood cells are needed every day in the U. S.

The blood plasma market is expanding due to increasing demand for plasma-derived therapies, advancements in technology, and rising awareness of chronic diseases. Key products include immunoglobulins, clotting factors, and albumin, which are crucial for treating conditions like haemophilia and autoimmune disorders. The market is primarily driven by therapeutic and diagnostic applications in hospitals, clinics, and research institutions. North America leads in market share, followed by Europe and Asia-Pacific, which are also experiencing significant growth. Challenges such as supply chain management, regulatory compliance, and ethical concerns impact the industry, while opportunities lie in emerging markets and innovative therapies. Overall, the market is dynamic with substantial growth potential.

Hong Kong Blood Plasma Market Dynamics

Market Growth Drivers

Some of the factors that will contribute include rising approval of Plasma products across the globe, also rising number of clinical researches that determines the safety and effectiveness of the products. Blood disorders like haemophilia and sickle cell anemia increase the need for plasma derived products. New policies for the promotion of plasma collection and increased public awareness about the benefits of plasma donations help the market. Recent improvements in the Plasma collection and processing make these therapies more effective and safer. As the healthcare expense grows across the world, especially in the developing nations, the growing research and development activities also open up new opportunities. Another factor that adds to the rise in consumption of plasma derivative products is the presence of senior citizens, a group that is most vulnerable to blood disorders.

Opportunity

As for the future prospects of the blood plasma market, there may be continued development of the new methods of fractionation to increase the productivity of products, and expansion of emerging economies, such as Asia Pacific and Latin America. Having own plasma collection centres guarantees constant availability of raw material, while constant R&D may result in new treatments. The adoption of digital health technologies supports operational improvements, while partnerships with key stakeholders propel advancement. Emphasizing the efficiency of proposed solutions will be helpful for global healthcare systems, and sustaining highly effective plasma systems will enhance public health readiness in emergency situations.

Market Restraints

Constraints that can slow down market growth and development include side effects arising from plasma-derived products, strict regulatory laws governing Industry and high production costs. Competition from other forms of treatment is another challenge; there would be few sources of donors as well. Perceptions and image factors, changes in the economic environment, and the technicalities of plasma collection and processing also pose challenges to the market. Mitigating these factors will therefore be critical in realizing sustainable growth and enhanced patient access to plasma derived products.

Competitive Landscape Blood Plasma Market in Hong Kong

Key Players

Recent Developments

March 2024, Scientists invent a coin-sized device to rapidly isolate blood plasma for diagnostics and precision medicine.

February 2024, GC's 'Alyglo', first S. Korea FDA-approved blood plasma to launch in US from July.

May 2025, PlasmaGen Biosciences Opens New, State-of-the-Art Manufacturing Facility for Blood Plasma Products in Kolar, Bengaluru.

March 2025, CSL's $470 Million Plasma Fractionation Facility Opens in Marburg, Germany.

March 2022, U.S. FDA Clears Terumo Blood and Cell Technologies' New Plasma Collection Technology.

Mergers and Acquisitions

February 2025, GC Biopharma acquired Catalyst Biosciences' rare disease hematology which includes "Marzeptacog alfa," an engineered factor VIIa that is ready for Phase 3 trials. This acquisition is intended to enhance GC Biopharma's presence in the blood plasma market, especially for treating rare bleeding disorders.

December 2025, Haier to Buy $1.8 Billion Stake in Chinese Blood Firm (1).

Healthcare Policies and Regulatory Landscape for Blood Plasma Market in Hong Kong

Blood Plasma in Hong Kong: rules and payment

Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health.⁠[1] Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government.⁠[2]

[1] Drug Office, Department of Health. Checked 14 Nov 2026.

[2] Hospital Authority. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Measures taken by the government for raising the level of plasma donation and the programs for the development of regional affordable blood product production are current strategies followed to cope with supply uncertainty and to increase the level of domestic production. The quality and safety of the products are regulated through legislation such as the WHO, and while it comes with some problems, problems for new entrants. This depends on the region; some regions have good coverage reimbursement policies while others have limited policies. Reimbursement system models aim at a new approach to payment for services, value-based care focuses on value for money, high production costs affect the prices. All the named factors influence the overall market developments in terms of availability, price, and utilization of plasma-derived therapies, which makes it necessary for actors to navigate such changes.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Blood Plasma right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 9 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Blood Plasma in context

Hong Kong compared

  • People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 16 countries we cover in APAC.[1]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

What segments does the Blood Plasma market report cover?
The report splits the market by type (Immunoglobulins, Albumin, Coagulation Factor Concentrates, Hyperimmune Globulin and more), application (Neurology, Immunology, Hematology, Critical Care and more) and end-user (Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes).
Who are the key players in the Blood Plasma market?
Key players include CSL Behring, Grifols, Octapharma, Kedrion Biopharma, Biotest LLC and LFB.
What is driving the Blood Plasma market?
Some of the factors that will contribute include rising approval of Plasma products across the globe, also rising number of clinical researches that determines the safety and effectiveness of the products.
Who regulates Blood Plasma in Hong Kong?
Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health. Source: Drug Office, Department of Health. Checked 14 Nov 2026.
How is healthcare paid for in Hong Kong?
Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government. Source: Hospital Authority. Checked 14 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Hong Kong

See all

Related on biologics and biosimilars

See the topic